PDCD1 and meningioma: The rationale for ICI use in meningioma (Table 3) is based on the expression of immune checkpoint molecules, including CTLA-4, PD-1, and PD-L1 in these tumors, with PD-L1 expression being proportional to tumor grade [49,50,51].